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Abstract Acquired demyelinating syndromes (ADS) can
be a first presentation of multiple sclerosis (MS) in chil-
dren. The incidence of these disorders in Europe is cur-
rently unknown. Children (\18 years old) living in the
Netherlands who presented with ADS were included from
January 1, 2007 to December 31, 2010 by the Dutch
pediatric MS study group and the Dutch surveillance of
rare pediatric disorders. Demographic and clinical data
were collected. Eighty-six patients were identified over
4 years, resulting in an incidence of 0.66/1,00,000 per year.
Most patients presented with polyfocal ADS without
encephalopathy (30%), followed by polyfocal ADS with
encephalopathy (24%), optic neuritis (ON, 22%), mono-
focal ADS (16%), transverse myelitis (3%), and
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neuromyelitis optica (3%). Patients with polyfocal ADS
with encephalopathy were younger (median 3.9 years) than
patients with ON (median 14.6 years, p \ 0.001) or
monofocal ADS (median 16.0 years, p \ 0.001). Patients
with polyfocal ADS without encephalopathy (median
9.2 years) were also younger than monofocal ADS patients
(median 16.0 years, p \ 0.001). There was a slight female
preponderance in all groups except the ON group, and a
relatively large number of ADS patients (29%) reported a
non-European ancestry. Familial autoimmune diseases
were reported in 23%, more often in patients with relapsing
disease than monophasic disease (46 vs. 15%, p = 0.002)
and occurring most often in the maternal family (84%,
p \ 0.001). During the study period, 23% of patients were
subsequently diagnosed with MS. The annual incidence of
ADS in the Netherlands is 0.66/1,00,000 children/year.
A polyfocal disease onset of ADS was most common.
Keywords Multiple sclerosis  Demyelinating diseases 
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Introduction
In the last decade, knowledge about pediatric multiple
sclerosis (MS) and other demyelinating diseases of the
CNS has increased considerably. As a group, these first
immune-mediated demyelinating events of the CNS are
referred to as acquired demyelinating syndromes (ADS)
[1]. They share common clinical characteristics and they
can all represent a first episode of MS. Due to increased
awareness among clinical professionals, these diagnoses
are likely to be made more often. At present, only one
prospective study reported about the incidence of ADS [1].
Other available incidence studies had a retrospective
design [2] or focused on subgroups of ADS, like acute
disseminated encephalomyelitis (ADEM) and MS [3].
In 2007, we started a nationwide prospective surveil-
lance study to define the incidence of ADS in the Nether-
lands. We used the network of collaborators of the Dutch
pediatric MS study group and participated in a nationwide
surveillance program to detect rare pediatric diseases in
which all Dutch pediatricians are involved. We here
describe the incidence as well as clinical and demographic
characteristics of children with ADS in the Netherlands.
Methods
Patient inclusion
Children younger than 18 years and living in the Nether-
lands and suspected of a first inflammatory demyelinating
event of the CNS who were detected by our surveillance
from 2007 to 2010 were included in this study.
Diagnoses were made in accordance to the criteria
proposed by the International Pediatric MS Study Group
(IPMSSG) [4]. Based on clinical and MRI data, patients
were divided into six ADS groups: (1) optic neuritis (ON),
(2) transverse myelitis (TM), (3) monofocal ADS (mono
ADS), (4) polyfocal ADS (poly ADS) without encepha-
lopathy, (5) polyfocal ADS with encephalopathy, and (6)
neuromyelitis optica (NMO). We avoided the term ADEM
[5], because of inconsistent use of this term in previous
studies and chose to define this group more transparently as
‘poly ADS with encephalopathy’ according to the defini-
tion proposed by the IPMSSG.
A diagnosis of MS was made in case of a second
demyelinating attack of the CNS with clinical and/or MRI
evidence of a new lesion localization at least 1 month after
onset. A patient who presented with poly ADS with
encephalopathy, required at least two new episodes without
encephalopathy, at least 3 months after onset, for a diag-
nosis of MS [4].
Patients were excluded if another cause of the neuro-
logical symptoms was demonstrated, including infectious,
metabolic, toxic, or systemic immunological causes.
The patients were identified using two methods, in order
to reach nationwide inclusion of patients:
• In the PROUDkids study (PRedicting the OUtcome of a
Demyelinating event in children) pediatric neurologists
of the eight Dutch academic hospitals and of five non-
academic neuropediatric hospitals are involved. The
aim of this study is to investigate prognostic factors that
predict MS diagnosis in children after ADS.
• The NSCK (Netherlands Paediatric Surveillance Unit)
reaches all Dutch pediatricians monthly by e-mail and
aims to provide insight in the epidemiology of rare
pediatric diseases in the Netherlands. Pediatricians
were asked to report whether they did or did not see a
patient suspected of a CNS inflammatory demyelinat-
ing disease.
Patients were included in the study after written
informed consent was obtained from parents and patients
older than 12 years. A standardized scoring template was
used to gather demographic and clinical information of all
reported patients. Demographic data consisted of sex, date,
and place of birth, ethnic background and family history in
first- and second-degree relatives. Country of birth and
ancestry was asked to both the child and his parents:
patients with at least one parent of non-European origin
were classified as of non-European origin. Whenever pos-
sible, we asked both parents about their family history with
emphasis on familial autoimmune diseases like autoim-
mune thyroid disease, rheumatoid diseases, and type I
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diabetes. Clinical data consisted of date of disease onset,
clinical symptoms, concomitant diseases, infection or
vaccination in preceding 4 weeks, hospitalization, and
treatment. MRI, blood, and CSF results were also collected
for diagnostic evaluation. Follow-up data were provided by
the treating physician and by telephone interview of the
parents at least once 2 years after disease onset. Clinical
records were then evaluated. We assessed whether diag-
noses changed during follow-up and the patient had to be
excluded. We also assessed whether a final diagnosis of
MS could be made.
The clinical, laboratory, and imaging data were reviewed
(by IAK) in order to ensure that patients met the inclusion
criteria and to diagnose them appropriately. This study was
approved by the Medical Ethical Committees of the Eras-
mus University Medical Centre in Rotterdam and of the
other participating centers.
Analysis
Demographical data of the Dutch population were derived
from Statistics Netherlands [6]. Statistical analysis was
performed using SPSS 17.0. The Kruskal–Wallis and Chi-
square tests were used to test differences in clinical and
demographic characteristics between the six groups.
Mann–Whitney U tests were used to follow-up differences
in numerical data between groups, whereas categorical data
were compared using Chi-square or Fisher’s exact tests.
A Bonferroni correction was applied, so all effects are
reported at a 0.0083 significance level.
The Chi-square test was also used to compare the ethnic
background of our patients with the Dutch population, to
compare the autoimmune family history between mono-
phasic and relapsing patients, and to compare seasonal
distribution in the entire group. Results were considered
significant if p \ 0.05. Unknown or not reported data in all
groups were removed from the analyses.
Results
From January 1, 2007 to December 31, 2010, 111 children
were reported. One child and her parents refused inclusion.
Eighty-six of the reported patients met the inclusion criteria
and were analyzed. Twenty-four reported patients (22%)
had an alternative diagnosis and were subsequently
excluded. The final diagnoses of the excluded patients are
listed in Table 1. The correct diagnoses were made by
laboratory tests, blood and CSF studies, MRI/MR angiog-
raphy, as well as clinical course and response to treatment.
Given the number of children in the Netherlands
younger than 18 years in 2007 (3,360,433), 2008 (3,344,
945), 2009 (3,329,173), and 2010 (3,314,663) [6], the
average incidence of ADS is 0.66/1,00,000 Dutch children
per year (0.60/1,00,000 in 2007, 0.60/1,00,000 in 2008,
0.72/1,00,000 in 2009, 0.72/1,00,000 in 2010).
Thirty percent of patients presented with poly ADS
without encephalopathy, 24% with poly ADS with
encephalopathy, 22% with ON, 16% with mono ADS, 3%
with TM, and 3% with NMO.
Figure 1 shows the distribution of the patients’ age at
clinical presentation. Children with poly ADS with
encephalopathy were younger (median 3.9 years) than
children with ON (median 14.6 years) (U = 29, p \0.001)
and children with monofocal ADS (median 16 years)
(U = 22, p \ 0.001). Also children with poly ADS without
Table 1 Diagnosis of the excluded patients
Diagnosis n = 24
Infectious disease 11
Viral encephalitis 6
Postinfectious TM 3
Meningitis 2
Systemic inflammatory or autoimmune disease 6
(Cerebral) vasculitis 3
Celiac disease 1
Susac’s syndrome 1
Hashimoto encephalopathy 1
Mitochondrial disease 4
Leber hereditary optic neuropathy (LHON) 1
Other 3
Neoplastic disease 2
Posterior reversible encephalopathy syndrome (PRES) 1
Fig. 1 Age distribution of the patients, categorized by clinical
presentation. The median age per group is shown. The horizontal
lines above the groups indicate statistical differences between the
groups (Mann–Whitney U test, *** p \ 0.001). ON optic neuritis, TM
transverse myelitis, ADS acquired demyelinating syndrome, mono
monofocal, poly polyfocal NMO neuromyelitis optica
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encephalopathy (median 9.2 years) were younger than
children with mono ADS (U = 63, p \ 0.001). No signifi-
cant differences were observed between the other groups.
The demographic characteristics of the included patients
are summarized in Table 2. The female–male distribution
was similar between the groups. After stratification of all
children with ADS in a group younger (n = 41) and a
group older than 10 years (n = 45), we also found a sim-
ilar female:male ratio of 1.3:1 in the younger and of 1.1:1
in the older group.
Twenty-five patients (29%) were of non-European ori-
gin. This proportion was higher than the proportion of
children of non-European origin (\18 years old) in the
general pediatric population in the Netherlands (16%) [6]
(v2 = 13.992, p \ 0.001). The incidence of ADS in chil-
dren of European origin is 0.52/1,00,000 per year, in
contrast to 1.16/1,00,000 per year in children of non-
European origin in the Netherlands. Most of these non-
European patients (84%) were born in the Netherlands
themselves.
A familial history of autoimmune diseases was present
in 23% of all patients. No difference was observed in the
presence of autoimmune diseases (including MS) in the
first- and second-degree relatives between the six ADS
subgroups. Autoimmune thyroid diseases and rheumatoid
arthritis were most frequently reported (both in five cases).
Only three ADS patients reported MS, all in the maternal
family. Familial autoimmune diseases occurred more often
in patients with relapsing disease than in patients with
monophasic disease (46 vs. 15%, v2 = 9.51, p = 0.002). A
maternal family history of autoimmune diseases was much
more frequent than a paternal family history of autoim-
mune diseases (84 vs. 16%, p \ 0.001).
In the ADS patients, we found no difference between a
disease onset in winter (36%), spring (21%), summer
(24%), or autumn (19%).
Table 3 shows the other clinical characteristics at first
demyelinating attack of the included patients. The differ-
ences in preceding infection between the groups did not
reach significance. Only one child received a vaccination
Table 2 Demographic characteristics of all patients, categorized by clinical presentation
ON
(n = 19)
TM
(n = 3)
Mono ADS
(n = 14)
Poly ADS
without
encephalopathy
(n = 26)
Poly ADS with
encephalopathy
(n = 21)
NMO
(n = 3)
p valuea All
(n = 86)
Female:male 0.9:1 2:1 1.3:1 1.4:1 1.1:1 2:1 0.97 1.2:1
European ethnicity,
n (%)
12 (63) 2 (67) 6 (43) 16 (62) 15 (71) 3 (100) 0.70 54 (63)
Non-European ethnicity,
n (%)
5 (26) 1 (33) 5 (36) 9 (35) 5 (24) 0 0.70 25 (29)
Middle-Eastern 2 (11) 0 0 2 (8) 1 (5) 0 5 (6)
African 1 (5) 0 4 (29) 2 (8) 1 (5) 0 8 (10)
Middle-American 1 (5) 0 1 (7) 1 (4) 0 0 3 (4)
Asian 0 0 0 1 (4) 1 (5) 0 2 (2)
Mixedb 1 (5) 1 (33) 0 3 (12) 2 (10) 0 7 (8)
Unknown ethnicity 2 (11) 0 3 (21) 1 (4) 1 (5) 0 0.42 7 (8)
Place of birth: outside
Europe, n (%)
1 (5) 0 1 (7) 2 (8) 0 0 0.81 4 (5)
Autoimmune family
history, n (%)
1 (5) 0 7 (50) 8 (31) 3 (14) 1 (33) 0.05 20 (23)
MS 1 (5) 0 1 (7) 0 0 1 (33) 0.18 3 (3)
Other autoimmune
disease
0 0 6 (43) 8 (31) 3 (14) 0 0.02c 17 (20)
Unknown family history 5 (26) 2 (67) 3 (21) 7 (27) 7 (33) 0 0.54 24 (28)
ON optic neuritis, TM transverse myelitis, ADS acquired demyelinating syndromes, mono monofocal, poly polyfocal, NMO neuromyelitis optica,
MS multiple sclerosis
a Patients between the six ADS groups are compared (v2 test for categorical data)
b Mixed ethnicity: one parent of European origin and one parent of non-European origin
c Not significant after Bonferroni correction
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(measles mumps and rubella vaccine) before onset of a
polyfocal disease with encephalopathy.
All patients (except one child with TM) underwent brain
MR imaging. Sixty-seven patients with ADS presented
with demyelinating lesions on brain MRI. Cerebral MRI
lesions were more frequent in children with mono ADS
(Fisher’s exact test, p = 0.001) and poly ADS with
encephalopathy (Fisher’s exact test, p \ 0.001) as com-
pared to children with ON.
Twenty-eight percent of the patients experienced at least
one relapse. One patient experienced two episodes of ON
after a poly ADS with encephalopathy (with resolution of
previous clinical symptoms and MRI abnormalities and
without new MRI lesions), one patient suffered from
another episode of poly ADS with encephalopathy and two
patients had recurrent ON without cerebral MRI lesions.
By now, 20 patients have been diagnosed as MS. More
patients with a monofocal onset (Fisher’s exact test,
p = 0.001) or a polyfocal onset without encephalopathy
(Fisher’s exact test, p = 0.003) were subsequently diag-
nosed with MS compared to patients with a polyfocal onset
with encephalopathy. Five patients were diagnosed as MS
based on asymptomatic new MRI lesions. The proportion
of patients with a relapsing disease who experienced their
second clinical attack within 2 years after onset (excluding
patients with only MRI evidence of new disease) was
comparable between the different diagnostic groups. Only
three children younger than 10 years experienced a second
clinical attack. The patients who were subsequently
diagnosed with MS were all older than 10 years at the time
of their first demyelinating attack.
Discussion
The incidence of ADS in children in the Netherlands is 0.66/
1,00,000 per year. It is difficult to compare this number with
the incidence in other countries because only two studies
defined and analyzed the incidence of ADS [1, 2] whereas
another study focused on solely ADEM and MS [3].
A nationwide prospective study in Canada reported an
annual incidence of ADS of 0.9/1,00,000 [1]. Both our
study and the Canadian study succeeded to reach nation-
wide coverage by using recently initiated centralized
national databases. The lower incidence observed in the
Netherlands may be explained in part by geographical
difference and differences in demographic characteristics
of the pediatric patients, especially regarding ethnicities. In
the Canadian group, 37% of children were first-generation
Canadians (i.e., both parents born outside Canada) [1]
whereas in the Netherlands this count was 18%.
A recent paper showed that the incidence of ADS in the
United States is 1.63/1,00,000 per year [2]. This is much
higher than our or the Canadian incidence. The main dif-
ference between this US and both our and the Canadian
study is the methodology: the US investigators retrospec-
tively searched a large health maintenance organization
database in one area. The incidence in this multiethnic
Table 3 Clinical characteristics of all patients, categorized by clinical presentation
ON
(n = 19)
TM (n = 3) Mono ADS
(n = 14)
Poly ADS without
encephalopathy
(n = 26)
Poly ADS with
encephalopathy
(n = 21)
NMO
(n = 3)
p valuea All
(n = 86)
Previous infection, n (%) 1 (5) 2 (67) 1 (7) 9 (35) 10 (48) 0 0.01b 23 (27)
Previous vaccination,
n (%)
0 0 0 0 1 (5) 0 0.70 1 (1)
Cerebral MRI pathology,
n (%)
8 (42) 0 14 (100) 23 (88) 21 (100) 1 (33) <0.001c 67 (78)
Follow-up time, months,
median (range)
14.3
(1.1–42.3)
9.9
(2.3–15.6)
21.4
(2.8–45.9)
12.5 (1.5–51.6) 13.2 (0.3–44.8) 7.3
(1.8–19.1)
0.66 12.9
(0.3–51.6)
Relapsing disease, n (%) 6 (32) 0 7 (50) 9 (35) 2 (10) 0 0.07 24 (28)
MS, n (%) 4 (21) 0 7 (50) 9 (35) 0 0 0.01b 20 (23)
Second clinical attack
B2 years, n (% of
relapsing patients)
5 (83) 0 6 (86) 5 (56) 2 (100) 0 0.37 18 (75)
ON optic neuritis, TM transverse myelitis, ADS acquired demyelinating syndromes, mono monofocal, poly polyfocal, NMO neuromyelitis optica, MRI
magnetic resonance imaging, MS multiple sclerosis
a Patients between the six ADS groups are compared (v2 test for categorical data and Kruskal–Wallis test for numerical data)
b Not significant after Bonferroni correction
c Mono ADS compared to ON (Fisher’s exact test, p = 0.001), poly ADS with encephalopathy compared to ON (Fisher’s exact test, p \ 0.001)
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cohort of Southern Californian children was then used to
extrapolate the incidence in the US. The question can be
raised of whether this study population is representative of
the entire US. Furthermore, the higher incidence may be
due to the large ethnic diversity in this cohort [2].
A nationwide German survey focused on children
(\16 years old) with ADEM and MS. They reported an
annual incidence of MS of 0.3/1,00,000 [3]. So far, we
found an annual incidence of MS of 0.15/1,00,000 in
Dutch children. This difference may be caused by the
still short follow-up time of the patients in our study.
The real incidence of pediatric MS in the Netherlands
can only be calculated when the youngest child of our
cohort reaches the cut-off age for pediatric ADS of
18 years. The higher incidence of MS in Germany can
also be due to their inclusion of both suspected as def-
inite MS patients [3].
A remarkable finding in the German study was the much
lower incidence of ADEM (0.07/1,00,000) [3]. The authors
speculated that this low number of ADEM patients could be
a consequence of geographical differences with other
cohorts [3]. Although ADEM was not defined in their study,
we found an annual incidence of patients with a polyfocal
onset with encephalopathy (ADEM according to the
IPMSSG [4]) of 0.16/1,00,000. So we could not confirm this
low incidence of ADEM in a geographical comparable area.
In our study, poly ADS without encephalopathy was the
most common presentation (30%), followed by poly ADS
with encephalopathy (24%) and ON (22%).
TM was very rare in our cohort (3%) in contrast to the
Canadian cohort (22%) [1]. The Canadian children with
TM differed from the Dutch children with TM: they were
much older (mean age at onset of 11 years) and MRI
abnormalities (either cerebral or spinal) were present in
91%. So there could be a discrepancy in defining TM. We
classified children with TM and clinical and/or MRI evi-
dence of a localization outside the spinal cord as either
polyfocal ADS or NMO. Children who were reported but
turned out to have a proven acute and active infectious
etiology were excluded.
Most patients had a European ancestry. However, the
incidence of ADS was twice as high in children of non-
European origin as in children of European origin in the
Netherlands. Most of these children were born in the
Netherlands themselves. Previous studies in Canada and
the US also showed that pediatric MS patients more fre-
quently had a non-European ancestry or were non-Cauca-
sian in contrast to adult MS patients, indicating that the
pediatric MS population reflects the changing immigration
patterns in countries with high MS prevalence. The dif-
ference may be explained by the possibility that children
with ancestors from a country with low MS prevalence
may lack protective genetic factors or are more vulnerable
to environmental factors when they grow up in a country
with high MS prevalence [2, 7, 8].
Familial MS was reported in only 3% of ADS patients,
which is in agreement with previous reports of numbers
varying between 3 and 8% [1, 3, 9]. This proportion is higher
in retrospective studies on pediatric MS and in studies with
longer follow-up durations [10, 11]. Next to MS, we found
that other autoimmune diseases in first- and/or second-
degree relatives were present in 20% of our patients.
Although this number is higher than reported in the Canadian
study [1], it is likely to be an underestimation, because the
family history was not reported in detail in 28% of patients.
Data on the presence of autoimmune diseases in the Dutch
pediatric population are not available. We observed that
familial autoimmune diseases were especially present in
patients with relapsing disease. Studies on the presence of
autoimmune diseases in first-degree relatives of adult MS
patients show contrasting results [12, 13], but the most recent
rigorously performed study suggests that autoimmune dis-
eases are not more frequent in families of MS patients [14].
Of particular interest is the observation that autoimmune
diseases were especially frequent in the maternal family. It
is not likely that this difference in autoimmune diseases
between the mother’s and father’s family is caused by the
possibility of only the mothers being the parent interviewed.
In all, except for one child, we were able to obtain infor-
mation on both parents. A maternal parent-of-origin effect
has been suggested for MS in adult patients [15–17]. To our
knowledge, a possible maternal transmission of autoim-
mune diseases has not been described before in either
pediatric ADS or MS patients or in adult MS patients.
It is plausible to expect that the incidence of ADS we
describe in this study is an underestimation because despite
all efforts, there are multiple reasons why it is impossible
to identify every patient in one country. Theoretically,
some ADS patients older than 16 years could have been
missed because they may have been directly referred to
adult neurologists. We do not expect this to be a large
number of patients in our study, as our MS center is a
national referral site for both pediatric and adult ADEM,
MS, and ADS variants. Secondly, patients with mild or
self-limiting symptoms may not be referred to a pediatri-
cian or neurologist at all. Thirdly, ophthalmologists did not
participate in this study, so we may have missed a number
of ON cases. Still, it is of note that the number of patients
with ON we observed is in accordance with a previously
reported incidence [1]. Finally, some physicians simply
may fail to report patients. However, the response rate in
the Dutch NSCK surveillance system is quite high. The
number of pediatricians that participated was 86.6% in
2007, 85.5% in 2008, and 84% in 2009 [18]. The strength
of our study is that we used two complementary methods to
enroll patients. By the NSCK, 44% of the patients were
1934 J Neurol (2012) 259:1929–1935
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identified and the remaining patients were identified by the
PROUDkids study group.
Our study illustrates that other disorders may mimic
ADS at first presentation (Table 1). It is important to
consider these disorders in the differential diagnosis of
ADS, because of potential treatment and prognosis.
ADS can be a challenging diagnosis, and knowing the
incidence can increase the awareness of these disorders in
children. This is relevant as there are indications of
increasing incidence, especially among certain ethnic
groups in the Western world.
The research on ADS in the Netherlands is still in pro-
gress and the aim is to provide long-term follow-up data in
the future.
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